Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation | terminated | Phase 2 | 150 | Fred Hutchinson Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03825289 | Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer(THREAD) | terminated | Phase 1 | 25 | University of UtahOTHER | 1 | May 14, 2026 |
| clinicaltrials |
| NCT04030559 | Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects | terminated | Phase 2 | 11 | University of California, DavisOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04559685 | Study of Sonodynamic Therapy in Participants With Recurrent High-Grade Glioma | terminated | Early Phase 1 | 10 | Nader SanaiOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05085002 | A Study of Lerociclib in Participants With Advanced Breast Cancer | terminated | Phase 2 | 100 | EQRx, Inc.INDUSTRY | 6 | May 14, 2026 | clinicaltrials |
| NCT05223036 | Testing Obeticholic Acid for Familial Adenomatous Polyposis | terminated | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 2 | May 14, 2026 | clinicaltrials |
| NCT05773326 | Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG | terminated | Early Phase 1 | 5 | Nader SanaiOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT02629692 | Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies | terminated | Phase 1 / Phase 2 | 124 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 10 | May 13, 2026 | clinicaltrials |
| NCT03757221 | Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma(IDARA) | terminated | Phase 2 | 55 | University Hospital, CaenOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03808610 | Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 53 | M.D. Anderson Cancer CenterOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06844669 | HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy | terminated | Phase 2 | 7 | Washington University School of MedicineOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03337698 | A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)(Morpheus Lung) | terminated | Phase 1 / Phase 2 | 314 | Hoffmann-La RocheINDUSTRY | 7 | May 12, 2026 | clinicaltrials |
| NCT03426371 | Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial | terminated | Phase 3 | 52 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 12, 2026 | clinicaltrials |
| NCT04746924 | A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer | terminated | Phase 3 | 669 | BeiGeneINDUSTRY | 19 | May 12, 2026 | clinicaltrials |
| NCT05582850 | DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours(EPRAD) | terminated | Phase 1 | 29 | Domain Therapeutics SAINDUSTRY | 2 | May 12, 2026 | clinicaltrials |
| NCT02928627 | Clinical Significance of Hepatic and Circulating microRNAs miR-221 and miR-222 in Hepatocellular Carcinoma | terminated | — | 10 | University of AberdeenOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06487858 | A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors | terminated | Phase 1 | 42 | BeOne MedicinesINDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT03382977 | Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects | terminated | Phase 1 / Phase 2 | 70 | VBI Vaccines Inc.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT04878952 | Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer | terminated | N/A | 3 | NRG OncologyOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05513027 | Augmented Whole-body Scanning Via Magnifying PET/CT (AWSM-PET/CT) Techniques Abilities to Improve Upon the Diagnostic Accuracy of the Standard-of-care (SOC) PET/CT for Malignant Lesion Detection | terminated | N/A | 11 | Washington University School of MedicineOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06149741 | Defunctioning Left-sided Colostomy in Low Anterior Resection for Rectal Cancer(STOMALEFT) | terminated | N/A | 16 | Umeå UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06295809 | A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)(INTerpath-007) | terminated | Phase 2 / Phase 3 | 46 | Merck Sharp & Dohme LLCINDUSTRY | 20 | May 8, 2026 | clinicaltrials |
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers | terminated | Phase 1 | 6 | PfizerINDUSTRY | 2 | May 8, 2026 | clinicaltrials |
| NCT05452681 | Piloting Y-AMBIENT: A Quality of Life Intervention for Young African American Breast Cancer Survivors | terminated | N/A | 27 | University of Alabama at BirminghamOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT05494658 | Impact of Preoperative Oral Branched-chain Amino Acids on Reducing Postoperative Insulin Resistance. | terminated | N/A | 79 | Sun PengOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT05820932 | Predicting Cognitive Decline From Androgen Deprivation Therapy(ABC) | terminated | — | 32 | University of California, San FranciscoOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06046066 | A Phase 1 Study of NM6603 in Advanced Solid Tumors | terminated | Phase 1 | 17 | NucMito Pharmaceuticals Co. Ltd.INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT07573787 | Homoeriodictyol Sodium Mouthwash to Reduce Chemotherapy Induced Bitter Taste Disorders(HED) | terminated | N/A | 15 | Christoph GrimmOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT02664389 | Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation(PANEL) | terminated | N/A | 289 | University Hospital, RouenOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03547700 | Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) | terminated | Phase 1 / Phase 2 | 11 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03684486 | Rehabilitation by Effort for Patients With Advanced Bronchial Cancer(RehabKBP) | terminated | N/A | 19 | University Hospital, ToulouseOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04331119 | Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas | terminated | Phase 2 | 17 | Washington University School of MedicineOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05027425 | Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant | terminated | Phase 2 | 8 | University of CincinnatiOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05050461 | Immune Response After SARS-CoV-2 (COVID-19) Vaccination in a Context of Non-Hodgkin Lymphoma(LYMPHO-CoVac) | terminated | N/A | 120 | Versailles HospitalOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05557292 | RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma | terminated | Phase 1 | 7 | Nicholas ButowskiOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05896163 | A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.(MAPtivate-6) | terminated | Phase 1 / Phase 2 | 40 | PfizerINDUSTRY | 4 | May 6, 2026 | clinicaltrials |
| NCT06617455 | Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial(VEnT) | terminated | Phase 2 | 9 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07159828 | A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 3 | Axion Bio, IncINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT01851395 | Rapid Autopsy and Procurement of Cancer Tissue | terminated | — | 32 | National Cancer Institute (NCI)NIH | 1 | May 5, 2026 | clinicaltrials |
| NCT02908048 | Extracellular RNA Markers of Liver Disease and Cancer | terminated | — | 1,865 | Mayo ClinicOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03506373 | Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia | terminated | Phase 2 | 21 | Mayo ClinicOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04034251 | Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis | terminated | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | May 5, 2026 | clinicaltrials |
| NCT04370522 | Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer(NIKOLE) | terminated | — | 32 | Spanish Breast Cancer Research GroupOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04786093 | Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC | terminated | Phase 2 | 1 | University of Texas Southwestern Medical CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05091866 | Natural Progesterone for the Treatment of Recurrent Glioblastoma | terminated | Early Phase 1 | 4 | Emory UniversityOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05812274 | Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients | terminated | N/A | 30 | Columbia UniversityOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05983133 | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors | terminated | Phase 1 | 68 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | May 5, 2026 | clinicaltrials |
| NCT02072616 | Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.(CTC-Pancreas) | terminated | N/A | 101 | University Hospital, RouenOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03173092 | A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) | terminated | Phase 4 | 141 | TakedaINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT03738553 | Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy | terminated | — | 13 | University of WashingtonOTHER | 1 | May 4, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 14, 2026source: clinicaltrials